Friday, December 18, 2020 by Joel Rose (NPR)
Katalin Karikó works at BioNTech, the company that partnered with Pfizer to make the first COVID-19 vaccine to get emergency authorization in the U.S.
Stay tuned in to our local news coverage: Listen to 90.7 WMFE on your FM or HD radio, the WMFE mobile app or your smart speaker say “Alexa, play NPR” and you’ll be connected.
Hungarian-born scientist Katalin Karikó believed in the potential of messenger RNA the genetic molecule at the heart of two new COVID-19 vaccines even when almost no one else did.
Karikó began working with RNA as a student in Hungary. When funding for her job there ran out, Kariko immigrated to Philadelphia in 1985. Over the years, she’s been rejected for grant after grant, threatened with deportation and demoted from her faculty job by a university that saw her research as a dead end.
If COVID-19 Vaccines Bring An End To The Pandemic, America Has Immigrants To Thank
By Joel Rose
December 18, 2020
Hungarian-born scientist Katalin Karikó believed in the potential of messenger RNA the genetic molecule at the heart of two new COVID-19 vaccines even when almost no one else did.
Karikó began working with RNA as a student in Hungary. When funding for her job there ran out, Kariko immigrated to Philadelphia in 1985. Over the years, she’s been rejected for grant after grant, threatened with deportation and demoted from her faculty job by a university that saw her research as a dead end.
Is IDYA A Good Stock To Buy Now? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 11, 2020
Rare Disease Gene Therapy Market: Snapshot
The global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide. Gene therapy is relevant to rare disease patients and has improved the wellbeing and personal satisfaction of more seasoned kids and youthful grown-ups with X-SCID. These kids are expected to experience complex clinical issues in the wake of getting live-sparing bone marrow transfers to treat the condition.
The report offers insights into the market emphasizing on factors boosting, repelling, challenging, and creating opportunities for the market in the forecast period. It also discusses the impact of the COVID-19 pandemic on the overall market. It also discusses the table of segmentation in details and lists the names of the prominent players functioning in the market.